ESR1 and breast carcinoma: For instance, the ER degrader vepdegestrant showed clinical activity and a safety profile in a phase 1/2 study, and it is currently under clinical evaluation in the VERITAC-2 phase 3 trial in pretreated patients with ER+/HER2- advanced breast cancer [126].